The first Phase II expansion cohorts will concentrate on renal cell carcinoma and melanoma.
The placebo-controlled and randomised study is anticipated to enrol around 60 patients with active RA.
The trial intends to recruit subjects with ANCA-RPGN, a severe and potentially fatal disease.
TEB-17231 has shown potent inhibition of tumour cell proliferation in vivo and in vitro in preclinical research.
The study will assess the tolerability, safety, pharmacokinetics, and pharmacodynamics of the therapy in healthy subjects.
Give your business an edge with our leading industry insights.
The company plans to administer the dose to a third patient early next year.
Change from baseline to week 12 on the HQ-CT score is the study’s primary efficacy endpoint.
Using the data from this study, the company is moving forward with a Phase I/II clinical trial in the Gambia, Africa.
The SCI-210 therapy combines cannabidiol and SciSparc’s Palmitoylethanolamide, designed to reduce autism spectrum disorder (ASD) symptoms.
The trial will enrol around ten patients at sites in Australia and the US.